Login to Your Account

Protalix Prices $23.6M Public Offering for ProCellEx Pipeline

By Catherine Shaffer
Staff Writer

Wednesday, February 22, 2012
Protalix Biotherapeutics Inc., of Carmiel, Israel, priced a public offering of 4.5 million shares at $5.25 per share, a 14.3 percent discount to Wednesday's closing price, which will bring in about $23.6 million in gross proceeds.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription